HBI-8000 in combination with nivolumab

DRUG2 trials

Sponsors

HUYABIO International, LLC.

Conditions

MelanomaNon-Small Cell Lung CancerProgressive Brain MetastasisRenal Cell CarcinomaUnresectable or Metastatic Melanoma

Phase 1

Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer

CompletedNCT02718066

HUYABIO International, LLC.Melanoma, Non-Small Cell Lung Cancer, Renal Cell Carcinoma

Start: 2016-08-18End: 2023-12-12Updated: 2026-07-30

Phase 3

Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma

Active, not recruitingNCT04674683

HUYABIO International, LLC.Progressive Brain Metastasis, Unresectable or Metastatic Melanoma

Start: 2021-08-12End: 2026-12-31Updated: 2025-09-24

Related Papers

797 Significant anti-tumor activity of HBI-8000, a class I histone deacetylase inhibitor (HDACi) in combination with nivolumab (NIVO) in anti-PD1 therapy-naïve advanced melanoma (TN-Mel)

2020-11-014 citations